Molecular Diagnosis & Therapy

, Volume 13, Issue 4, pp 209–215 | Cite as

Circulating Tumor Cells as Markers for Cancer Risk Assessment and Treatment Monitoring

Current Opinion
First Online:

Abstract

Carcinomas of epithelial origin represent the majority of malignancies in Europe. A substantial number of patients develop recurrent carcinoma, which is explained by tumor-cell dissemination into distant organs, preferentially bone marrow, which often occurs prior to surgery. In contrast to disseminated tumor cells in bone marrow, for which the prognostic value has been demonstrated, the role of circulating tumor cells (CTCs) in blood is not yet completely understood. Since bone marrow aspiration is less accepted by patients than blood withdrawal, it would be highly desirable to replace bone marrow aspiration by blood analysis. Presently, a variety of seemingly promising methods for the detection and characterization of CTCs are under evaluation, including immunocytologic and molecular approaches. However, these methods still need to be proven useful in clinical studies. The majority of studies published on CTCs to date have been related to primary and metastatic breast cancer; therefore, this article mainly addresses the role of CTCs in breast cancer.

Keywords

Breast Cancer Epidermal Growth Factor Receptor Trastuzumab Human Epidermal Growth Factor Receptor Metastatic Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

No sources of funding were used to assist in the preparation of this article. The author has no conflicts of interest that are directly relevant to the content of the article.

References

  1. 1.
    Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumor cells. Nat Rev Cancer 2008 May; 8(5): 329–40PubMedCrossRefGoogle Scholar
  2. 2.
    Husemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008 Jan; 13(1): 58–68PubMedCrossRefGoogle Scholar
  3. 3.
    Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micro-metastasis in breast cancer. N Engl J Med 2005 Aug 25; 353(8): 793–802PubMedCrossRefGoogle Scholar
  4. 4.
    Kasimir-Bauer S, Mayer S, Bojko P, et al. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy. Clin Cancer Res 2001 Jun; 7(6): 1582–9PubMedGoogle Scholar
  5. 5.
    Braun S, Kentenich C, Janni W, et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000 Jan; 18(1): 80–6PubMedGoogle Scholar
  6. 6.
    Wiedswang G, Borgen E, Karesen R, et al. Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome. Clin Cancer Res 2004 Aug 15; 10(16): 5342–8PubMedCrossRefGoogle Scholar
  7. 7.
    Becker S, Becker-Pergola G, Wallwiener D, et al. Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy. Breast Cancer Res Treat 2006 May; 97(1): 91–6PubMedCrossRefGoogle Scholar
  8. 8.
    Fehm T, Braun S, Muller V, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006 Sep 1; 107(5): 885–92PubMedCrossRefGoogle Scholar
  9. 9.
    Borgen E, Pantel K, Schlimok G, et al. A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow: results from analysis of normal bone marrow. Cytometry B Clin Cytom 2006 Nov 15; 70(6): 400–9PubMedGoogle Scholar
  10. 10.
    Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007 Dec 20; 450(7173): 1235–9PubMedCrossRefGoogle Scholar
  11. 11.
    Pachmann K, Camara O, Kavallaris A, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008 Mar 10; 26(8): 1208–15PubMedCrossRefGoogle Scholar
  12. 12.
    Krivacic RT, Ladanyi A, Curry DN, et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A 2004 Jul 20; 101(29): 10501–4PubMedCrossRefGoogle Scholar
  13. 13.
    Hsieh HB, Marrinucci D, Bethel K, et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006 Apr 15; 21(10): 1893–9PubMedCrossRefGoogle Scholar
  14. 14.
    Alix-Panabieres C, Vendrell JP, Pelle O, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007 Mar; 53(3): 537–9PubMedCrossRefGoogle Scholar
  15. 15.
    Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004 Aug 19; 351(8): 781–91PubMedCrossRefGoogle Scholar
  16. 16.
    Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006 Jul 15; 12 (14 Pt 1): 4218–24PubMedCrossRefGoogle Scholar
  17. 17.
    Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007 Feb 1; 13(3): 920–8PubMedCrossRefGoogle Scholar
  18. 18.
    Shaffer DR, Leversha MA, Danila DC, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007 Apr 1; 13(7): 2023–9PubMedCrossRefGoogle Scholar
  19. 19.
    Bosma AJ, Weigelt B, Lambrechts AC, et al. Detection of circulating breast tumor cells by differential expression of marker genes. Clin Cancer Res 2002 Jun; 8(6): 1871–7PubMedGoogle Scholar
  20. 20.
    Ring AE, Zabaglo L, Ormerod MG, et al. Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 2005 Mar 14; 92(5): 906–12PubMedCrossRefGoogle Scholar
  21. 21.
    Baker MK, Mikhitarian K, Osta W, et al. Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology. Clin Cancer Res 2003 Oct 15; 9(13): 4865–71PubMedGoogle Scholar
  22. 22.
    Hauch S, Zimmermann S, Lankiewicz S, et al. The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. Anticancer Res 2007 May–Jun; 27(3A): 1337–41PubMedGoogle Scholar
  23. 23.
    Sieuwerts AM, Kraan J, Bolt J, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009 Jan 7; 101(1): 61–6PubMedCrossRefGoogle Scholar
  24. 24.
    Demel U, Tilz GP, Foeldes-Papp Z, et al. Detection of tumour cells in the peripheral blood of patients with breast cancer: development of a new sensitive and specific immunomolecular assay. J Exp Clin Cancer Res 2004 Sep; 23(3): 465–8PubMedGoogle Scholar
  25. 25.
    Zieglschmid V, Hollmann C, Gutierrez B, et al. Combination of immuno-magnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Res 2005 May–Jun; 25(3A): 1803–10PubMedGoogle Scholar
  26. 26.
    Cristofanilli M, Broglio KR, Guarneri V, et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer 2007 Feb; 7(6): 471–9PubMedCrossRefGoogle Scholar
  27. 27.
    National Cancer Institute Clinical Trials (PDQ®). Phase III randomized study of treatment decision making based on levels of circulating tumor cells in women with metastatic breast cancer undergoing chemotherapy [online]. Available from URL: http://www.cancer.gov/clinicaltrials/SWOG-S0500 [Accessed 2009 Jun 9]
  28. 28.
    Tewes M, Aktas B, Welt A, et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 2009 Jun; 115(3): 581–90PubMedCrossRefGoogle Scholar
  29. 29.
    Vincent-Salomon A, Couturier C, Nos X, et al. HER2 gene status assessment in micrometastatic cells in bone marrow (BM) of breast cancer patients by fluorescence in situ hybridization [abstract no. 9520]. J Clin Oncol 2004; 22 (14S) [online]. Available from URL: http://meeting.ascopubs.org/cgi/content/abstract/22/14_suppl/9520 [Accessed 2009 Jun 8]
  30. 30.
    Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004 Dec 15; 10(24): 8152–62PubMedCrossRefGoogle Scholar
  31. 31.
    Becker S, Becker-Pergola G, Fehm T, et al. HER2 expression on disseminated tumor cells from bone marrow of breast cancer patients. Anticancer Res 2005 May–Jun; 25(3B): 2171–5PubMedGoogle Scholar
  32. 32.
    Solomayer EF, Becker S, Pergola-Becker G, et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 2006 Jul; 98(2): 179–84PubMedCrossRefGoogle Scholar
  33. 33.
    Stathopoulou A, Vlachonikolis I, Mavroudis D, et al. Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002 Aug 15; 20(16): 3404–12PubMedCrossRefGoogle Scholar
  34. 34.
    Giatromanolaki A, Koukourakis MI, Kakolyris S, et al. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. Int J Cancer 2004 Feb 10; 108(4): 620–7PubMedCrossRefGoogle Scholar
  35. 35.
    Gaforio JJ, Serrano MJ, Sanchez-Rovira P, et al. Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts for poor prognosis. Int J Cancer 2003 Dec 20; 107(6): 984–90PubMedCrossRefGoogle Scholar
  36. 36.
    Jotsuka T, Okumura Y, Nakano S, et al. Persistent evidence of circulating tumor cells detected by means of RT-PCR for CEA mRNA predicts early relapse: a prospective study in node-negative breast cancer. Surgery 2004 Apr; 135(4): 419–26PubMedCrossRefGoogle Scholar
  37. 37.
    Pierga JY, Bonneton C, Vincent-Salomon A, et al. Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 2004 Feb 15; 10(4): 1392–400PubMedCrossRefGoogle Scholar
  38. 38.
    Benoy IH, Elst H, Philips M, et al. Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 2006 Mar 13; 94(5): 672–80PubMedGoogle Scholar
  39. 39.
    Camara O, Rengsberger M, Egbe A, et al. The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol 2007 Sep; 18(9): 1484–92PubMedCrossRefGoogle Scholar
  40. 40.
    Pachmann K, Camara O, Kavallaris A, et al. Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring. Breast Cancer Res 2005; 7(6): R975–9PubMedCrossRefGoogle Scholar
  41. 41.
    Mehes G, Witt A, Kubista E, et al. Circulating breast cancer cells are frequently apoptotic. Am J Pathol 2001 Jul; 159(1): 17–20PubMedCrossRefGoogle Scholar
  42. 42.
    SUCCESS study portal [online]. Available from URL: http://www.success-studie.de/ [Accessed 2009 Jun 9]
  43. 43.
    Jenderek C, Jückstock J, Schindlbeck C, et al. Minimal residual disease detection in peripheral blood of primary breast cancer patients: translational research in the SUCCESS-study [abstract no. 5019]. San Antonio Breast Cancer Symposium; 2008 Dec 10–14; San Antonio (TX) [online]. Available from URL: http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L__772&terms = [Accessed 2009 Jun 9]
  44. 44.
    German Breast Group, GeparQuattro-Trial. English overview: a randomized phase III study exploring the efficacy of capecitabine given concomitantly or in sequence to EC-Doc with or without trastuzumab as neoadjuvant treatment of primary breast cancer [online]. Available from URL: http://www.germanbreastgroup.de/geparquattro/english.html [Accessed 2009 Jun 9]
  45. 45.
    Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008 Nov 1; 14(21): 7004–10PubMedCrossRefGoogle Scholar
  46. 46.
    Hayes DF, Walker TM, Singh B, et al. Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int J Oncol 2002 Nov; 21(5): 1111–7PubMedGoogle Scholar
  47. 47.
    Braun S, Schlimok G, Heumos I, et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 2001 Mar 1; 61(5): 1890–5PubMedGoogle Scholar
  48. 48.
    Fehm T, Becker S, Duerr-Stoerzer S, et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res 2007; 9(5): R74PubMedCrossRefGoogle Scholar
  49. 49.
    Bast RC, Ravdin P, Hayes DF, et al. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001 Mar 15; 19(6): 1865–78PubMedGoogle Scholar
  50. 50.
    Ditsch N, Mayer B, Rolle M, et al. Estrogen receptor expression profile of disseminated epithelial tumor cells in bone marrow of breast cancer patients. Recent Results Cancer Res 2003; 162: 141–7PubMedCrossRefGoogle Scholar
  51. 51.
    Fehm T, Krawczyk N, Solomayer EF, et al. ERα-status of disseminated tumor cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008; 10(5): R76PubMedCrossRefGoogle Scholar
  52. 52.
    Reuben JM, Lee BN, Li C, et al. Genomic of circulating tumor cells in metastatic breast cancer [abstract no. 1002]. J Clin Oncol 2007; 25 (18S) [online]. Available from URL: http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/1002 [Accessed 2009 Jun 8]
  53. 53.
    Pantel K, Schlimok G, Kutter D, et al. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res 1991 Sep 1; 51(17): 4712–5PubMedGoogle Scholar
  54. 54.
    Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993 Sep 1; 85(17): 1419–24PubMedCrossRefGoogle Scholar
  55. 55.
    Italiano A, Saint-Paul MC, Caroli-Bosc FX, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann Oncol 2005 Sep; 16(9): 1503–7PubMedCrossRefGoogle Scholar
  56. 56.
    Wiedswang G, Borgen E, Schirmer C, et al. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer 2006 Apr 15; 118(8): 2013–9PubMedCrossRefGoogle Scholar
  57. 57.
    Bidard FC, Vincent-Salomon A, Gomme S, et al. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 2008 Nov 1; 14(21): 7004–10PubMedCrossRefGoogle Scholar
  58. 58.
    Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006 Oct 1; 12(19): 5615–21PubMedCrossRefGoogle Scholar
  59. 59.
    Theodoropoulos PA, Polioudaki H, Sanidas E, et al. Detection of circulating tumor cells with breast cancer stem cell-like phenotype in blood samples of patients with breast cancer [abstract no. 2008]. 99th Annual Meeting, American Association for Cancer Research; 2008 Apr 12–16; San Diego (CA) [online]. Available from URL: http://aacrmeetingabstracts.org/search.dtl [Accessed 2009 Jun 8]
  60. 60.
    Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44+/CD24−/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005 Feb 1; 11(3): 1154–9PubMedGoogle Scholar
  61. 61.
    Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007 Nov; 1(5): 555–67PubMedCrossRefGoogle Scholar
  62. 62.
    Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002 Jun; 2(6): 442–54PubMedCrossRefGoogle Scholar
  63. 63.
    Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008 Oct; 8(10): 755–68PubMedCrossRefGoogle Scholar
  64. 64.
    Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004 Aug 6; 118(3): 277–9PubMedCrossRefGoogle Scholar
  65. 65.
    Watson MA, Ylagan LR, Trinkaus KM, et al. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res 2007 Sep 1; 13(17): 5001–9PubMedCrossRefGoogle Scholar
  66. 66.
    Aktas B, Tewes M, Fehm T, et al. Stem cell and epithelial-mesenchymal transition markers are frequently expressed in metastatic breast cancer patients with circulating tumor cells. Breast Cancer Res. In pressGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Department of Gynecology and Obstetrics, University Hospital EssenUniversity of Duisburg-EssenEssenGermany

Personalised recommendations